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Background: Despite rising healthcare costs, generic drugs are less frequently dispensed in Japan compared with
other developed countries. This study aimed to describe changes in dispensing of branded and generic drugs and
to explore possible factors that promote the use of generic drugs.
Methods: We conducted a retrospective cohort study using a Japanese medical and pharmacy claims database. All
proton pump inhibitors (PPIs) and histamine H2-receptor antagonists (H2RAs) with indications for gastroesophageal
reflux disease (GERD) described on Japanese labels were included. Patterns of dispensing branded and generic
drugs for the treatment of GERD between 2006 and 2011 were analyzed. Multivariate logistic regression was
applied to investigate factors associated with receiving generic drugs.
Results: The study cohort included 14,590 patients (male: 50.2%, mean age: 43.1 years). Branded drugs for GERD
were still frequently dispensed despite an increase in the share of generic drugs. Only 4.3% of patients who initially
received branded drugs switched to generic drugs. The percentage of patients who received only generic drugs
increased over time (6.5% to 22.1%). The frequency of generic drug dispensing was the highest in the setting
where both prescription and dispensing were implemented in clinics (43.3%), while the lowest in the setting where
both prescription and dispensing were implemented in hospitals (11.5%). Factors associated with receiving generic
drugs included year of dispensing (adjusted OR 2.22, 95% CI 1.94 to 2.55 for 2009–11 v 2006–8), prescription and
dispensing setting (OR 1.81, 95% CI 1.44 to 2.26 for prescription in hospitals and dispensing in community
pharmacies; OR 2.21, 95% CI 1.80 to 2.72 for prescription in clinics and dispensing in community pharmacies; and
OR 4.55, 95% CI 3.68 to 5.62 for prescription and dispensing in clinics v prescription and dispensing in hospitals)
and H2RAs (OR 1.64, 95% CI 1.49 to 1.81 compared to PPIs).
Conclusions: The share of generic drugs for the treatment of GERD increased over time although branded drugs
for GERD were still dispensed frequently. The use of generic drugs for GERD was influenced not only by
government policies but also by changes in treatment approach and the setting of prescription and dispensing.
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Generic drugs can help reduce healthcare costs and pa-
tients’ co-payments with replacement of more expensive
branded drugs including the same active molecule which
have expired the patents. To date, several policies and
measures have been enacted to promote the use of gen-
eric drugs by the Ministry of Health, Labour and Wel-
fare in Japan, with some moderate success seen in
increasing the share of generic drugs (18.7% in 2007 to
22.8% in 2011 in volume share) [1-5]. The measures in-
cluded, for example, modification of the prescription
form and incentive for generic drug prescribing and dis-
pensing to medical institutions and pharmacies. How-
ever, despite the increase in total healthcare costs being
a concern in Japan, the share of generic drugs is still
much lower than in other developed countries [6,7].
The use of commercially available generic drugs is not
mandatory in Japan. At present, physicians, pharmacists
and patients are all involved in the process of selecting
branded or generic drugs. For example, when physicians
want their patients to use branded drugs, they can in-
struct pharmacists not to dispense generic drugs [8].
Conversely, even when physicians permit patients to use
generic drugs, pharmacists and patients can refuse gen-
eric drugs and patients can receive branded drugs in-
stead. According to recent surveys, approximately 70 to
90% of the general public or patients were aware of gen-
eric drugs and only 10% of the general public or patients,
physicians, and pharmacists viewed them negatively
[9-11]. However, concerns remained over the quality and
stable supply of generic drugs in Japan [9].
The utilization of generic drugs has been investigated
in terms of therapeutic areas rather than specific diseases
or drug classes in Japan [12,13]. In the Netherlands, more
patients treated with omeprazole switched to other
branded molecules of proton pump inhibitors (PPIs) after
the patent expiration of omeprazole [14]. In the United
States, generic forms of statins, such as pravastatin and
simvastatin, substituted for branded atorvastatin from the
observation of share trend within statins [15]. Generic
anti-epileptic drugs were not admissible to patients in
comparison to other long-term therapies with generic
forms of anti-hyperlipidemics and anti-depressants [16].
Such detailed analyses of drug utilization would give ef-
fective implications for promotion of generic drugs.
Gastroesophageal reflux disease (GERD) is one of the
most common gastrointestinal disorders; the prevalence
of patients experiencing at least weekly reflux symptoms
is reported as 6.5 to 9.5% in Japan [17-19]. Most patients
with GERD are treated with acid-suppressive drugs in
outpatient settings. PPIs are the first-line for the treat-
ment of GERD but histamine H2-receptor antagonists
(H2RAs) can also be used [20]. In this study, PPIs and
H2RAs for GERD were considered appropriate forinvestigating the utilization and the impact of generic
drugs, as both branded and generic drugs were commer-
cially available during the study period. We analyzed the
changing patterns of dispensing of branded and generic
drugs for the treatment of GERD.
Methods
Data source
This was a retrospective cohort study using a medical
and pharmacy claims database established by the Japan
Medical Data Center Co., Ltd. (JMDC, Tokyo, Japan)
[21,22]. The Japanese healthcare system is characterized
by a universal health care coverage provided by employee-
based or community-based plans and free access to clinics
and hospitals. The claims database for the study, which
comprises data from multiple employee-based insurances,
was launched in 2005 with approximately 320,000 popula-
tion and, as of 2010, includes approximately 1 million
population. The database includes data on patient demo-
graphics such as encrypted personal identifiers, year of
birth, sex, medical practices such as diagnosis, treatments,
drugs dispensed, test orders, and type of medical insti-
tution and pharmacy and type of service (inpatient or
outpatient). Diagnosis was defined according to the
10th revision of the International Classification of Dis-
eases (ICD-10) [23] and standardized diagnoses pro-
vided by the Medical Information System Development
Center (MEDIS-DC) [24].
Prescription and dispensing procedure
In Japan, patients receive prescribed drugs via an in-
house or community pharmacy. To date, it was shown
that the share of generic drugs differed by prescription
and dispensing procedure (ie, prescribing and dispensing
separated or integrated) and larger hospitals used less
generic drugs [25]. Therefore, we classified the prescrip-
tion and dispensing process into four patterns according
to the combinations of medical institution (hospital or
clinic) and pharmacy (in-house or community) as fol-
lows: 1) prescription and dispensing in a hospital (in-
hospital dispensing), 2) prescription and dispensing in a
clinic (in-clinic dispensing), 3) prescription in a hospital,
but dispensing in a community pharmacy (out-hospital
dispensing), and 4) prescription in a clinic, but dispens-
ing in a community pharmacy (out-clinic dispensing).
Clinics are defined as medical institutions with less than
20 beds, whereas hospitals are defined as medical insti-
tutions with 20 or more beds in Japan.
Patients
We used claims data from April 2006 to December 2011
to identify new patients with GERD. We defined new pa-
tients as those who did not have previous diagnoses of
GERD in the last six months. Patients eligible for the
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dispensing of PPIs or H2RAs for the treatment of GERD
in an outpatient setting. The initial diagnosis was limited
to reflux esophagitis, GERD, or non-erosive GERD, and
from the second diagnosis, intractable reflux esophagitis
and intractable reflux esophagitis requiring maintenance
treatment were also included according to the MEDIS-
DC. PPIs or H2RAs dispensed more than six months
after the completion of a series of initial treatments for
new patients were regarded as treatments for the relapse
of GERD and excluded in the analysis.
The following exclusion criteria were set to exclude
non-GERD patients and to investigate the conditions at
the initial dispensing and switching of branded and
generic drugs clearly: 1) patients who were diagnosed
with GERD but received no PPIs or H2RAs, 2) patients
who could not be followed up for more than six
months after the initial diagnosis, 3) patients who re-
ceived drugs to be taken “as needed” at the initial dis-
pensing, 4) dosing duration of the initial dispensing <7
or >56 days, 5) patients who received oral medicines of
non-steroidal anti-inflammatory drugs or corticoste-
roids with PPIs or H2RAs at the initial dispensing, and
6) patients who received more than one PPIs and/or
H2RAs at the initial dispensing or at switching between
branded and generic drugs.
Drugs of interest
All branded and generic drugs with indications for
GERD described on Japanese labels were included in the
study. These were omeprazole, lansoprazole, rabepra-
zole, and esomeprazole as PPIs, and famotidine, raniti-
dine, cimetidine, roxatidine, nizatidine, and lafutidine as
H2RAs. Generic rabeprazole was marketed in November
2010, and branded esomeprazole was marketed in Sep-
tember 2011. No generic lafutidine was available during
the study period. Both branded and generic drugs were
commercially available for the other molecules through-





1. Branded (once) 6328 (43.4) 3256 (51.5
2. Generic (once) 1385 (9.5) 644 (46.5)
3. Branded (≥twice) 4979 (34.1) 2476 (49.7
4. Generic (≥twice) 1000 (6.9) 476 (47.6)
5. Branded to Generic (switched once) 486 (3.3) 261 (53.7)
6. Generic to Branded (switched once) 198 (1.4) 106 (53.5)
7. Started with Branded (switched multiple times) 142 (1.0) 62 (43.7)
8. Started with Generic (switched multiple times) 72 (0.5) 42 (58.3)
SD: standard deviation, PPIs: proton pump inhibitors, H2RAs: histamine H2-receptorAnalysis
The dispensing patterns and time trends of drug
utilization were examined. Eligible patients were divided
into two groups based on whether branded or generic
drugs were initially dispensed, then into four subgroups
based on switching patterns and frequency of dispensing
(Table 1). Age, sex, and drugs dispensed (PPIs or
H2RAs) were summarized using descriptive statistics for
all patients and for each group. Patients stratified by the
eight dispensing patterns were presented in chrono-
logical order when they were initially dispensed to
analyze time trends of dispensing patterns. The time
trends of frequencies of generic drug dispensing were in-
vestigated according to the four types of prescription
and dispensing settings based on type of medical institu-
tion and pharmacy. The volume and value shares by
branded or generic, PPIs or H2RAs, and individual mole-
cules were calculated over time. The shares were calcu-
lated based on IMS’s methods of standard unit [26,27].
Conditions at switching between branded and generic
drugs were analyzed in detail in patients who experi-
enced switching once. Multivariate logistic regression
was performed to investigate factors associated with re-
ceiving generic drugs using data at the initial dispensing.
Covariates included sex, age, year of dispensing, setting
of prescription and dispensing, and drugs dispensed. Ad-
justed odds ratios (OR) and 95% confidence intervals
(CI) were reported as well as P values. Analysis was per-
formed with IBM SPSS Statistics Version 20 and 21. The
protocol of this study was approved by ethics commit-
tees at both Kyoto University Graduate School and Fac-
ulty of Medicine and the JMDC which has a licence for
secondary use of the claims data.
Results
Dispensing patterns
A total of 14,590 patients (male: 50.2%) were included,
and mean (±SD) age at the initial dispensing was 43.1
(±12.2) years. The percentage of patients who receivedAge (years)
mean ± SD
Initial dispensing All dispensing
% of PPIs % of H2RAs % of PPIs % of H2RAs
) 41.3 ± 11.8 82.0 18.0 n/a n/a
40.7 ± 11.8 70.8 29.2 n/a n/a
) 45.0 ± 12.3 79.7 20.3 79.0 21.0
45.3 ± 12.5 76.6 23.4 77.7 22.3
47.3 ± 12.1 82.9 17.1 80.5 19.5
43.9 ± 12.4 58.6 41.4 78.7 21.3
46.3 ± 12.6 81.0 19.0 81.5 18.5
47.5 ± 12.7 62.5 37.5 76.5 23.5
antagonists.
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pensing, 81.8% of patients received branded drugs, and
79.4% of patients received PPIs. Analysis of eight dis-
pensing patterns showed that the majority of patients re-
ceived only branded drugs; once (43.4%, pattern 1) and
multiple times (34.1%, pattern 3) (Table 1). In contrast,
the percentage of patients who received only generic
drugs was 16.3%; once (9.5%, pattern 2) and multiple
times (6.9%, pattern 4). Among the patients receiving
PPIs and/or H2RAs multiple times, only a small percent-
age switched between branded and generic drugs. At the
initial dispensing, patients who received branded drugs
(patterns 1, 3, 5, and 7) were more likely to receive PPIs
than those who received generic drugs (compared with
patterns 2, 4, 6, and 8, respectively). Patients switching
from generic to branded drugs were more likely to re-
ceive PPIs after the switch (patterns 6 and 8).
Changes of dispensing patterns over time
Dispensing patterns changed over time as shown in
Figure 1. The percentage of patients who received only
generic drugs (patterns 2 and 4) increased over time
(6.5% at the first term to 22.1% at the last term), while
that of patients who received only branded drugs (pat-
terns 1 and 3) decreased (90.0% to 71.4%). The percent-
age of patients who started with branded drugs and then
switched to generic drugs increased (1.8% to 3.3%).Figure 1 Changes in dispensing patterns of branded and generic druPrescription and dispensing procedure
The frequency of generic drug dispensing steadily in-
creased over time in all the four prescription and dis-
pensing patterns (Figure 2). It was highest for in-clinic
dispensing (43.3% at the last term), but lowest for in-
hospital dispensing (11.5%). A similar trend was ob-
served in out-clinic and out-hospital dispensing.Share trend
Trends of volume and value shares are shown in Figure 3.
As of December 2011, the shares of generic drugs
accounted for 36.8% in volume and 23.3% in value
(Figures 3-1a and 3-1b). The volume share of PPIs
slightly increased due to the rise in generic PPIs (Figure 3-
2a). The volume share of generic PPIs increased to a
greater extent than that of generic H2RAs, while that of
both branded PPIs and H2RAs decreased. The volume
share of each molecule showed that generic lansoprazole,
omeprazole and rabeprazole increased and branded lanso-
prazole and famotidine decreased (Figures 3-3a and 3-3c).
The other branded and generic H2RAs roughly remained
static in volume share over the study period and did
not completely compensate for the decrease of branded
famotidine. As PPIs are generally more expensive than
H2RAs, the value share of H2RAs was low (Figures 3-
2b, 3-3b, and 3-3d).gs over time.
Figure 2 Differences in frequencies of generic drug dispensing by prescription and dispensing settings.
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We analyzed the conditions of switching in detail using
data of patients who switched from branded to generic
drugs once (n = 486; pattern 5 in Table 1) and generic to
branded drugs once (n = 198; pattern 6). In patients ex-
perienced switching from branded to generic drugs, the
majority of patients received drugs in the same drug
class (PPIs: 66.3% and, H2RAs: 10.3%), but remaining
23.5% changed drug class, with 71.9% of them changed
from PPIs to H2RAs. In terms of the changes in mole-
cules, more than half of patients (58.0%) received the
same molecule. In contrast, in patients experienced
switching from generic to branded drugs, 54.0% of pa-
tients received drugs in the same drug class (PPIs: 46.0%
and, H2RAs: 8.1%), while 46.0% changed drug class, with
74.7% of them changed from H2RAs to PPIs. Only 19.2%
received the same molecule, and switching from generic
famotidine to branded drugs of lansoprazole (11.6%) and
rabeprazole (12.6%), and from generic drugs of omepra-
zole or lansoprazole to rabeprazole (17.2%) were ob-
served. In addition, 16.7% changed medical institutions
at the time of switching from branded to generic drugs
and 29.8% from generic to branded drugs.
Factors associated with receiving generic drugs
The results of multivariate logistic regression analysis indi-
cated that age and sex were not associated with receiving
generic drugs (Table 2). Meanwhile, factors associated
with receiving generic drugs included year of dispensing
(adjusted OR 2.22, 95% CI 1.94 to 2.55 for 2009–11 v
2006–8), prescription and dispensing setting (OR 1.81,
95% CI 1.44 to 2.26 for prescription in hospitals and dis-
pensing in community pharmacies; OR 2.21, 95% CI 1.80to 2.72 for prescription in clinics and dispensing in com-
munity pharmacies; and OR 4.55, 95% CI 3.68 to 5.62 for
prescription and dispensing in clinics v prescription and
dispensing in hospitals) and H2RAs (OR 1.64, 95% CI 1.49
to 1.81 compared to PPIs).
Discussion
This retrospective observational study showed that
branded drugs were still frequently used between 2006
and 2011 in Japan despite an increase in the share of
generic drugs. We also found that generic PPIs replaced
not only the corresponding branded PPIs but also the
different molecules of PPIs after the introductions to the
market. Changes in shares of individual molecules within
a drug class have also been reported in other studies
[14,15].
In addition, we demonstrated that generic PPIs might
replace branded H2RAs in the patients with GERD. The
substitution of branded H2RAs with generic PPIs could
be related not only to government implementation of
generic drugs but also to the change in approach to
treating GERD. A GERD management guideline was
published by the Japanese Society of Gastroenterology in
November 2009, with PPIs recommended as first-line
drugs [20], however, a rapid shift of dispensing from
H2RAs to PPIs was not observed following this publica-
tion (Figure 3). We therefore speculated that studies of
clinical efficacy [28] and cost-effectiveness [29-31] on
PPIs, and the activities of the Society for GERD [32] had
contributed to steady increase in the dispensing of PPIs.
Furthermore, the affordable price, availability, and dur-
ation of marketing of generic PPIs may also have facili-
tated the replacement from H2RAs to PPIs.
Figure 3 Volume and value shares of branded and generic drugs by drug classes and molecules. (1a) overall volume share, (1b) overall value
share, (2a) volume share by drug class, (2b) value share by drug class, (3a) volume share of PPIs, (3b) value share of PPIs, (3c) volume share of H2RAs,
(3d) value share of H2RAs.
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Table 2 Factors associated with receiving generic drugs at initial dispensing
Variables Reference Adjusted odds ratio (95% CI) P value
Female Male 1.04 (0.95 to 1.13) 0.39
Age: <45 years old ≥45 years old 1.02 (0.94 to 1.11) 0.65
Dispensing: 2009–2011 2006–2008 2.22 (1.94 to 2.55) <0.001
Out-hospital dispensing In-hospital dispensing 1.81 (1.44 to 2.26) <0.001
Out-clinic dispensing In-hospital dispensing 2.21 (1.80 to 2.72) <0.001
In-clinic dispensing In-hospital dispensing 4.55 (3.68 to 5.62) <0.001
H2RAs PPIs 1.64 (1.49 to 1.81) <0.001
CI: confidence interval, H2RAs: histamine H2-receptor antagonists, PPIs: proton pump inhibitors.
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cedure showed that the frequency of generic drug dis-
pensing was only 11.5% in the last period of in-hospital
dispensing (Figure 2). One general reason for infrequent
dispensing of generic drugs might be the higher profit
margin of branded drugs derived from the difference be-
tween wholesale and reimbursement prices [8,33]. How-
ever, this could not explain the disparity of the
proportion of generic drugs between in-clinic and in-
hospital dispensing. It is likely that other factors influ-
ence the selection of branded or generic drugs, including
stubborn resistance to generic drugs, economic burdens
due to the stock of various generic drugs, and the pre-
miums for the use of generic drugs on remuneration for
medical services. Further research is needed to clarify
reasons why generic drugs were dispensed infrequently
in in-hospital dispensing settings compared with other
prescription and dispensing settings because there is
more room for promoting the use of generic drugs.
Changes in dispensing patterns suggested a potentially
effective approach to promoting generic drugs. The per-
centage of patients who received generic drugs once or
multiple times from the initial dispensing increased over
time, whereas the percentage of patients who switched
from branded to generic drugs remained very small.
Thus, starting treatment with generic drugs would be
more acceptable for patients and/or medical profes-
sionals compared to switching from branded to generic
drugs once treatment was initiated. Therefore, we con-
sidered that a more active approach to the use of generic
drugs from the initiation of treatment onwards was
needed. Our findings on the initial dispensing of GERD
treatments suggested that prescribing in hospitals, espe-
cially dispensing in in-house pharmacies adversely af-
fected the use of generic drugs. More research is needed
to identify the reasons that underlie these observations.
Limitations to the present study need to be acknowl-
edged. The claims database includes only a small pro-
portion of people over 60 years of age. The study was
biased towards a younger population than that for actual
patients with GERD [34]. Treatments and selections of
branded or generic drugs for GERD observed in thestudy may be different from those in older patients. In
addition, the data available was limited to years and
months in medical claims hence we compiled the data
on a monthly basis. The accuracy of diagnosis of GERD
written on claims could potentially have its limits since
GERD was potentially diagnosed in claims in order to
prescribe PPIs or H2RAs even if the patient is not actu-
ally suffering from GERD. We therefore attempted to re-
move non-GERD patients by setting strict inclusion and
exclusion criteria.
The detailed analysis of the conditions at switching
suggested that the treatment strategy for GERD might
influence the selection of branded or generic drugs. Pa-
tients who changed the medical institutions and
switched from H2RAs to PPIs might have uncontrolled
GERD and received more intensive treatment in other
medical institutions. We could not specify the reasons
for switching from this study with claims data in which
only a small percentage of patients experienced switch-
ing between branded and generic drugs. Further studies
are required in order to clarify underlying problems in
the use of generic drugs, such as dissatisfaction of pa-
tients or physicians, policy of medical institutions and
pharmacies, drug stocks [35], or cultural, industrial or
policy factors such as patients’ experiences with generic
drugs [36], market competition [36], and drug-price
margin [8] in the context of Japan.Conclusions
This study revealed that branded drugs for GERD were
still dispensed frequently despite an increase in the share
of generic drugs. Changes in the approach to treating
GERD and prescription and dispensing setting also
seemed to influence the dispensing of generic drugs as
well as government implementation. Our findings based
on generic drugs utilization in patients with the specific
disease will give useful implications for physicians to in-
crease their awareness about prescribing generic drugs
and for policy makers to conduct further implementa-
tion of generic drugs with a more accurate understand-
ing of the use of generic drugs.
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